Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Seeking Alpha17d
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Eli Lilly's operational performance is strong ... The only difference is that under the Mounjaro label, the drug can only be used for treating those with diabetes. Year over year, revenue for ...
The Motley Fool25d
Prediction: These 3 Healthcare Stocks Will Soar in 2025
First, tirzepatide, which it markets as Zepbound and Mounjaro, could earn label ... Eli Lilly's work in the weight loss area looks particularly exciting. Its late-stage pipeline features ...
Hosted on MSN19d
LLY Falls Around 14% in 3 Months: How to Play the Stock
Eli Lilly and Company’s LLY ... company increases production capacity. Also, Lilly looks well placed to get approval for several new drugs and label expansions for marketed drugs, including ...
Yahoo Finance3d
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Patrik Jonsson is an executive vice president at Eli Lilly and president of Lilly Cardiometabolic ... It took a while to become popular as an off-label weight loss aid. Once it did, demand ...
Investing5d
Eli Lilly stock dips on Novo Nordisk's rival drug data
Retatrutide, Eli Lilly's drug candidate under development, showed around a 20% placebo-corrected weight loss at a similar stage in its trial but was tested in heavier patients. Novo Nordisk's ...